Research programme: GR Inflammation - Karo PharmaAlternative Names: GR Inflammation
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Class Glucocorticoids
- Mechanism of Action Glucocorticoid receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Sweden
- 02 Apr 2012 Early research in Inflammation in Sweden (unspecified route)